Clinical Outcome of Cefiderocol for Infections with Carbapenem-Resistant Organisms
Cefiderocol is a novel cephalosporin recently approved by the FDA to aid clinicians in the fight against multidrug-resistant (including carbapenem-resistant) gram-negative organisms. The primary objective of this study is to evaluate the 14- and 28-day mortality associated with cefiderocol. We perfo...
Αποθηκεύτηκε σε:
| Κύριοι συγγραφείς: | , , |
|---|---|
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
MDPI AG
2023-05-01
|
| Σειρά: | Antibiotics |
| Θέματα: | |
| Διαθέσιμο Online: | https://www.mdpi.com/2079-6382/12/5/936 |
| Ετικέτες: |
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|